Explore /
Poster
/ Anamorelin in patients with advanced non-small cell lung cancer and cachexia: Results from the phase III studies ROMANA 1 and 2.

Anamorelin in patients with advanced non-small cell lung cancer and cachexia: Results from the phase III studies ROMANA 1 and 2.

Abstract

Poster

Authors

Jennifer S. Temel

Massachusetts General Hospital, Boston, MA

Jennifer S. Temel, David Christopher Currow, Kenneth Fearon, Ying Yan, John Friend, Amy Pickar Abernethy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2015 Palliative and Supportive Care in Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Biologic Basis of Symptoms and Treatment Toxicities,Psycho-oncology,End-of-Life Care,Survivorship,Evaluation and Assessment of Patient Symptoms and Quality of Life,Management/Prevention of Symptoms and Treatment Toxicities,Integration and Delivery of Palliative Care in Cancer Care,Psychosocial and Spiritual Care,Communication in Advanced Cancer

Sub Track

Symptom management

Clinical Trial Registration Number

NCT01387269, NCT01387282

Citation

J Clin Oncol 33, 2015 (suppl 29S; abstr 175)

DOI

10.1200/jco.2015.33.29_suppl.175

Abstract #

175

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2013 ASCO Annual Meeting

Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia.

First Author: Amy Pickar Abernethy

Poster

2022 ASCO Annual Meeting

Body weight (BW) response timing to anamorelin (ANAM) in advanced non–small cell lung cancer (NSCLC)–associated cachexia.

First Author: Richard J.E. Skipworth

Poster

2016 Palliative and Supportive Care in Oncology Symposium

Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m<sup>2</sup>): Post-hoc analysis of two phase III studies.

Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m²): Post-hoc analysis of two phase III studies.

First Author: David Christopher Currow

Poster

2016 ASCO Annual Meeting

Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m<sup>2</sup>): A pooled efficacy data analysis of two phase 3 studies.

Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m²): A pooled efficacy data analysis of two phase 3 studies.

First Author: David Christopher Currow

FEATURED

Anamorelin in patients with advanced non-small cell lung cancer and cachexia: Results from the phase III studies ROMANA 1 and 2.

Authors

Jennifer S. Temel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia.

Poster

Body weight (BW) response timing to anamorelin (ANAM) in advanced non–small cell lung cancer (NSCLC)–associated cachexia.

Poster

Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): Post-hoc analysis of two phase III studies.

Poster

Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): A pooled efficacy data analysis of two phase 3 studies.

Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m²): Post-hoc analysis of two phase III studies.

Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m²): A pooled efficacy data analysis of two phase 3 studies.